Boya Bio-Pharmaceutical Group finalizes second phase fund agreement

Boya Bio-Pharmaceutical Group announced the signing of the "China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) Limited Partnership Agreement" on October 28, 2025. This follows the company's prior announcement on July 18, 2025, regarding its participation in the establishment of the China Resources Pharmaceutical Industry Investment Fund Phase II. The key terms of the recently signed agreement remain substantially consistent with those disclosed earlier.

The company will act as a limited partner, committing its own capital to subscribe for a total of RMB 60 million, representing a 6% ownership interest in the fund. The total fund size is RMB 1 billion. This investment is aimed at implementing the company's development strategy, effectively managing early-stage innovation project risks, and securing high-quality strategic project resources to enhance long-term sustainable growth and profitability.

The investment is aligned with the company's strategic plan, enhancing its ability to acquire and allocate quality resources. This participation is not expected to negatively impact the company’s continuous operations, profitability, or asset position, nor will it result in new controlling subsidiaries or changes to the consolidated financial statements. The fund is managed by Shenzhen CR Capital Equity Investment Co., Ltd.